Insilico Medicine, ISM6331, Generative AI, Cancer Drug Development, Mesothelioma, TEAD Inhibitor, Oncology, Phase 1 Clinical Trial, Precision Medicine, Chemistry42, ESMO 2026, Biotechnology

Cambridge, Massachusetts, U.S., October 25, 2026 Insilico Medicine has reported encouraging preliminary clinical findings for ISM6331, an investigational cancer...